Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tarpeyo
Pharma
Asahi Kasei moves to buy Calliditas for more than $1B
Bolstered by a full approval for its primary immunoglobulin A nephropathy drug Tarpeyo, Calliditas has earned the attention of Japan's Asahi Kasei.
Fraiser Kansteiner
May 28, 2024 11:19am
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
Dec 20, 2023 5:24pm
Calliditas launches IgA kidney disease education campaign
May 20, 2022 9:35am
